ImClone VEGF Development Program Expands, Gains Insurance With UCB Deal
This article was originally published in The Pink Sheet Daily
Fifty-fifty partnership will co-develop UCB’s CDP-791 for use in solid tumors while ImClone continues work on in-house oncologic IMC-1121B.
You may also be interested in...
ImClone will develop IMC-1121B after the biologic demonstrated promising clinical activity in Phase I, firm says.
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.